SCHEMBL3853274

SCHEMBL3853274

CCC(N)C(C)(C)O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3852175 1.00
SCHEMBL3852239 1.00
Hydrochloric Acid SCHEMBL1371062 0.97
Hydrochloric Acid SCHEMBL1371065 0.97
Hydrochloric Acid SCHEMBL28693809 0.97
SCHEMBL27973595 0.79
SCHEMBL993291 0.78
SCHEMBL18410645 0.77 TSHR (0.33)
SCHEMBL18130910 0.77
SCHEMBL1525883 0.77

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240076291-A1 MODIFIED ISOINDOLINONES AS GLUCOSYLCERAMIDE SYNTHASE INHIBITORS MERCK SHARP & DOHME LLC (US) 2024-03-07 US disclosed
WO-2023239645-A1 SMARCA DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2023-12-14 WO disclosed
WO-2023220435-A1 COMPOSITIONS USEFUL FOR MODULATING SPLICING SKYHAWK THERAPEUTICS, INC. (US) 2023-11-16 WO disclosed
US-11299457-B2 Chemical compounds GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) 2022-04-12 US disclosed
US-20200270210-A1 CHEMICAL COMPOUNDS GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED 2020-08-27 US disclosed
US-20200270210-A1 CHEMICAL COMPOUNDS GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED 2020-08-27 US disclosed
US-10710963-B2 Chemical compounds GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) 2020-07-14 US disclosed
US-10710963-B2 Chemical compounds GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) 2020-07-14 US disclosed
US-20190127326-A1 CHEMICAL COMPOUNDS GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) 2019-05-02 US disclosed
US-20190127326-A1 CHEMICAL COMPOUNDS GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) 2019-05-02 US disclosed
EP-1529047-B1 NEW PURINE DERIVATIVES CYCLACEL LTD (GB) 2007-02-21 EP disclosed
EP-1399446-B1 2,6,9-SUBSTITUTED PURINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF PROLIFERATIVE DISORDERS CYCLACEL LTD (GB) 2005-08-03 EP disclosed
EP-1529047-A2 NEW PURINE DERIVATIVES Cyclacel Limited (GB) 2005-05-11 EP disclosed
US-20050009846-A1 2,6,9-Substituted purine derivatives and their use in the treatment of proliferative disorders CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2005-01-13 US disclosed
EP-1399446-A1 2,6,9-SUBSTITUTED PURINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF PROLIFERATIVE DISORDERS Cyclacel Limited (GB) 2004-03-24 EP disclosed
WO-2004016612-A2 NEW PURINE DERIVATIVES CYCLACEL LIMITED (GB) 2004-02-26 WO disclosed
WO-2003002565-A1 2,6,9-SUBSTITUTED PURINE DERIVATIVES AND THEIR USE N THE TREATMENT OF PROLIFERATIVE DISORDERS CYCLACEL LIMITED (GB) 2003-01-09 WO disclosed
US-6441254-B1 REACTING FORMALDEHYDE AND ALDEHYDE IN PRESENCE OF A NITROGEN BASE TO FORM MIXTURE CONTAINING TRIMETHYLOL COMPOUND AND FORMATE SALT OF NITROGEN BASE; REMOVING TRIMETHYLOL COMPOUND; DISTILLATION OF FORMATE SALTS INTO BASE AND FORMIC ACID BAYER AKTIENGESELLSCHAFT (DE) 2002-08-27 US disclosed
WO-1991019693-A1 ESTERS AND CYCLIC DIESTERS OF 4-HYDROXY-1,3-BENZENEDIMETHANOL AND COMPOSITIONS AND METHODS EMPLOYING SUCH COMPOUNDS SCHERING CORPORATION (US) 1991-12-26 WO disclosed
US-4096186-A HYDROGENATION CATALYSTS TEIJIN LIMITED (JA) 1978-06-20 US disclosed